MicroRNA (miRNA; miR) is a class of small regulatory RNA molecules, the aberrant expression of which can lead to the development of cancer. We recently reported that overexpression of miR-21 and/or miR-155 leads to activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway in malignant lymphomas expressing CD3
Introduction
The genes responsible for T-cell and natural killer (NK)-cell lymphoma/leukemia are largely unknown because specific translocations have not yet been identified, although analyses to determine genomic copy number alterations revealed a 6q21 deletion, which is seen in about 10-20% of T and NK/T-cell lymphomas. [1] [2] [3] [4] [5] [6] [7] [8] Cancer cells gain a survival advantage by adding to abilities such as cell proliferation, anti-apoptotic function and immortalization. These changes are caused by altering the expression of oncogenes and/or tumor suppressor genes/proteins, such as c-Myc, Bcl2 and p53, among many others. In addition, recently discovered microRNAs (miRNAs) are known to associate with tumorigenesis and to alter the expression of both oncogenes and tumor suppressor genes. [9] [10] [11] [12] miRNAs are a class of small RNA molecules that have a regulatory function and have important roles in tumor development by pairing with the 3 0 -untranslated region (UTR) of target mRNAs to repress their productive translation. [9] [10] [11] [12] Various miRNA alterations have been identified in lymphoma/leukemias, as well as in solid tumors, irrespective of the presence or absence of disease-specific genomic/genetic alterations. [9] [10] [11] [12] We recently observed that two oncomiRs (miR-21 and miR-155) are overexpressed in NK/T-cell lymphoma, and that they contribute to lymphomagenesis by enhancing anti-apoptotic function. These miRNAs downregulate phosphatase and tensin homolog (PTEN), programmed cell death 4 and Src homology-2 domaincontaining inositol 5-phosphatase 1 (SHIP1) while upregulating phosphorylated AKT ser473/4 . 13 These findings suggest that activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway is important for NK/T-cell lymphomagenesis. Consistent with that idea, Huang et al.
14 recently used gene expression profiling to show the importance of activation of PI3K-AKT pathway in NK/T-cell lymphoma. Taken together, these results suggested miR-21 and miR-155 are upstream regulators of PI3K-AKT signaling.
In that context, the aim of the present study was to investigate the role of aberrantly downregulated miRNAs in T-and NK-cell lymphoma by using miRNA arrays, Northern blotting and quantitative PCR to examine miRNA expression in NK-cell and CD56
þ T-cell lymphoma lines. We found that expression of miR-150 is significantly diminished in both cell lines and in samples of primary lymphoma. We then tested the effects of transducing miR-150 to NK/T-cell lymphoma lines to determine whether it might function as a tumor suppressor.
Materials and methods
Lymphoma cell lines NK and NK/T-cell lymphoma lines. We used 11 cell lines as NK/T-cell lymphoma leukemia cell lines, which are commonly showing CD2 þ , sCD3 À , CD3e þ , CD5 À , CD56 þ , TCRab À and TCRgd À phenotypes, including NKL, KHYG-1, YT, KAI-3, NK-92, HANK-1, SNK-1, SNK-6, DERL-7, SNK-10 and MOTN-1. [13] [14] [15] [16] [17] [18] Of these, YT, KAI-3, HANK-1, SNK-1, SNK-6 and SNK-10 are EBV þ . 15, 16 Although MOTN-1 was established from T-cell large granular lymphocyte leukemia, the cell line is showing NK-cell antigen. 17 
CD56
þ T-cell lymphoma lines. We also used five CD56 Primary lymphoma samples and normal NK and T cells NK/T-cell lymphoma/leukemia. Nine samples of 'extranodal NK/T cell lymphoma, nasal type' and three samples of 'aggressive NK-cell leukemia' were collected from 12 patients. Out of 12 cases, 11 were previously used for miRNA analysis. 13 The remaining one case is described in Results section in this paper. These samples were positive for CD56, EBV infection or cytotoxic molecules such as TIA1 and GranzymeB. T cells showing the sCD3 (n ¼ 15) and NK cells showing the sCD3 À CD56 þ phenotype (n ¼ 14) were also collected from healthy donors using a magnetic cell sorting system (Miltenyi Biotec., Bergisch Gladbach, Germany)or cell sorter (Dako Cytomation MoFlo; Dako, Glostrup, Denmark). Polyclonal IL-2-activated NK cells were expanded in Iscove's modified Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% human serum, 100 U/ml recombinant IL-2 (Hoffmann-La Roche, Basel, Switzerland) and 10% purified human IL-2 (Hemagen, Columbia, MD, USA). Resting NK cells were resuspended in the same medium without IL-2 and were used within 4 days after isolation. These cells were 95-99% CD3 À CD56 þ , as determined by flow cytometry. All the samples were obtained from tumors at the time of diagnosis before any treatment was administered. Samples were obtained under protocol approved by the Institutional Review Board of Akita University.
miRNAs expression analyses
We performed miRNA array, Northern blot analysis and Taqman PCR analysis. Detail is described in Supplementary Methods. Ninety probes used for Northern blot and expression pattern of miRNAs are described in Supplementary Table 2 .
Construction of plasmids and transduction
Lentiviral vectors for the delivery of miRNAs were designed and produced using the reagents and protocols included in the BLOCK-iT Lentiviral Pol II miR RNA interference expression system (Invitrogen). Detailed method is described in Supplementary Methods. The premicro-RNA (miR-150) inserted vector was transfected using Lipofectamine 2000 into 293FT producer cells. After overnight culture, the medium was replaced to remove the transfection reagents, and viral supernatants were collected the following day (72 h after transfection). Viral supernatants were applied to lymphoma cell lines. After removing the medium, the cells were cultured for an additional 48 h, and green fluorescent protein (GFP) þ cells were collected using a cell sorter (Dako Cytomation MoFlo). In this study, we defined 'day 0' as the day on which lymphoma cells were sorted for GFP-miR-150 positivity: 48 h after either miR-150-GFP or GFP infection.
Antisense oligonucleotide assays
Antisense oligonucleotides (ASOs) and their respective scrambled control oligonucleotides were synthesized as hybrid deoxyribonucleotide molecules linked between the 2 0 -O and 4 0 -C-methylene bridge (locked nucleic acid) modification of G and C residues (Greiner, Tokyo, Japan) as described previously.
13,19
Cell growth assay /well, MOTN-1, SNK-6 and HANK-1) cultured in 96-well plates were transferred to 12-well plates, after which viable cells were identified by trypan blue exclusion and counted on days from 0 to 63 from miR-150 selection (at 2-65 days after transduction).
Cell proliferation assay (5'-bromo-2'-deoxyuridine assay)
Cell proliferation was assessed using a BrdU Cell Proliferation Assay kit (Merck, Darmstadt, Germany) following the manufacturer's protocol.
Apoptosis assay
An annexin V-PE apoptosis detection kit (BD Biosciences, San Jose, CA, USA) was used to assess the incidence of apoptosis among GFP þ cells. Cells were exposed to 100 mM etoposide for 4 h, after which the assays were carried out.
Senescence-associated b-gal assay
Senescence-associated beta-gal was assayed using a Senescence Detection Kit (BioVision, Mountain View, CA, USA) according to the manufacturer's protocol.
Telomerase activity (telomeric repeat amplification protocol) assay
Telomerase activity was assayed using a TRAP EZE Gel-Based Telomerase Detection Kit (Millipore, Billerica, MA, USA). Cells (3 Â 10 5 ) were suspended in CHAPS lysis buffer, and PCR was performed according the manufacturer's instructions.
Southern blot analysis
DNA (5 mg) was digested with HinfI and transferred to Hybond N membranes (GE Healthcare Japan, Tokyo, Japan).
Western blot analysis
Antibodies against phospho-AKT ser473/4 (pAKT), total AKT, AKT2 and c-Myc were all purchased from Cell Signaling Technology (Danvers, MA, USA; Cell Cycle Regulation Sampler Kit). Antip53 (DO-7) was from Dako Cytomation and anti-Bim (AAP-330) was from Stressgen Bioreagents (Funakoshi, Tokyo, Japan). Dyskerin (gene name: DKC1) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Tumor suppressor miR-150 in malignant lymphoma A Watanabe et al
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Results
Detection of candidate tumor suppressor miRNAs in NK/T-cell lymphomas
To identify aberrant expression of miRNAs in NK/T-cell lymphomas/leukemias, we initially carried out miRNA arrays with normal (sCD3 À CD56 þ ) NK cells and seven NK/T-cell lymphoma/leukemia lines (YT, KAI-3, KHYG-1, NKL, NK-92, HANK-1 and SNK-6). We found that expression of 37 out of 858 hsa-miRNAs was recurrently (two and more) reduced in the lymphoma cells, as compared with normal NK cells (Supplementary Table 2 ). To validate the expression of these miRNAs in NK/T-cell lymphomas/leukemias, we carried out Northern analyses with normal NK, T-cell and various lymphoma lines using 90 probe sets, which included candidate oncomiRs in various cancers (let-7, miR-15, miR-221 and so on), [10] [11] [12] as well as hematopoietic-specific miRNAs (miR-16, miR-451 and miR-223 and so on) (Supplementary Table 2) . 20, 21 The lymphoma cell lines used included those showing a sCD3 À CD56 þ phenotype (YT, KAI-3, NK-92, NKL, DERL-7, HANK-1, MOTN-1 and SNK-6), two T-cell lymphoma/leukemia lines (sCD3 þ ) (MyLa and JM) and two B-cell lymphoma lines (Raji and Daudi). Figure 1 shows the miRNA expression in four samples of normal/resting NK (sCD3 À CD56 þ ) cells and eight sCD3 À CD56 þ lymphoma lines. Northern analyses revealed that let-7e, miR-29c, miR-30e, miR-125a, miR-150, miR-181a and miR-223 were more highly expressed in NK cells than in the sCD3 À CD56 þ lymphoma cell lines. These differences were particularly evident in the case of miR-150 in NK-cell. For these candidate miRNAs, we also conducted Taqman quantitative PCR analysis using RNA collected from normal NK cells (n ¼ 11), NK/T-cell lymphoma/leukemia lines (n ¼ 11), and primary NK/T-cell lymphoma samples (n ¼ 11) (Supplementary Figure 1 ). This analysis confirmed that expression of miR-150, but not the other miRNAs tested, was significantly (Po0.05) higher in normal NK cells than in either the lymphoma cell lines or the primary lymphoma samples.
Aberrantly reduced expression of miR-150 in NK/T-cell lymphoma
Quantitative PCR revealed high levels of miR-150 expression in normal sCD3
þ T, and sCD3 
, as well as samples of primary NK/T-cell lymphoma/leukemia (n ¼ 12). We also compared expression of miR-150 in resting and activating NK cells and found that both the groups showed strong expression of miR-150, and that there was no significant difference between them (Figure 2b 
Transduction of miR-150 into lymphoma lines and % GFP monitoring
To determine the role of miR-150 in the tumorigenesis of NK/T-cell lymphomas, we transduced miR-150 along with GFP into five NK/T-cell lymphoma cell lines (YT, KAI-3, MOTN-1, SNK-6 and HANK-1) and two B-cell lymphoma cell lines (Raji and Daudi). The transduction efficiencies were as follows: YT, (Figure 3a ). Quantitative PCR also showed upregulation of miR-150 in all transduced cell lines (Figure 3b ). Expressions of miR-150 of all cell lines between normal and GFP þ vector-transduced cells showed no differences in the expressions (data not shown).
After initially monitoring % GFP among cells in culture, the conditions for lentiviral infection were adjusted to achieve B50% GFP-miR-150 positivity among recipient cells (1:1 mixture of B100% GFP þ cells and GFP À cells), after which the mixed cultures were monitored weekly using a flow cytometer. Figure 3c shows the changes in %GFP-miR-150 among HANK-1 cells from day 7 to day 28 after GFP-miR-150 selection. We observed a reduction in %GFP-miR-150 beginning at 14 days after GFP-miR-150 selection, which might have been caused by displacement of GFP À cells. As shown in Figure 3d , a reduction in %GFP-miR-150 was seen in the YT, MOTN-1, HANK-1 and SNK-6 lines, but not in KAI-3 cells or in the two B-cell lymphoma lines, whereas the cell lines transduced with GFP vector did not show the reduction in any cell lines examined. Transduced SNK-6 cells showed a slight upregulation of miR-150 when compared with other transduced cell lines. This effect might be linked to a lower 'decreasing rate (75-80%)' than was seen with the other transduced cells such as MOTN-1 and HANK-1.
miR-150 increases susceptibility to apoptosis and reduces cell proliferation in NK/T-cell lymphoma cell lines
To detect the function of miR-150 during tumorigenesis, we assessed the incidence of apoptosis among transduced cells following exposure to etoposide (100 mM for 4 h) on day 14 after selection. We found that the incidence of apoptosis in the presence of etoposide was increased in MOTN-1 cells (Figure 4a ). When we then carried out 5'-bromo-2'-deoxyuridine assays with MOTN-1 cells, we found that the 5'-bromo-2'-deoxyuridine index was significantly reduced in cells transduced with miR-150 (Figure 4b ). The same results were obtained in HANK-1 cells (Figures 4c and d) . Although SNK-6 cells did not show increased apoptosis when transduced with miR-150 alone, greater numbers of apoptotic cells were detected when the miR-150 was transduced into miR-155 knockdown cells ( Figure 5) . Similarly, miR-150-positive MOTN-1 and HANK-1 cells expressing ASO-155 did not show a significant increase in the incidence of apoptosis (Supplementary Figure 3) . In addition, apoptosis assays with YT cells revealed a cooperative effect between miR-21 and miR-150. YT cells transduced with miR-150 showed significantly larger numbers of apoptotic cells if they were treated with ASO-21 ( Figure 5 ). Moreover, combining miR-150 transduction with miR-21 knockdown induced significant increases in the incidence of apoptosis. In addition, when we carried out 5'-bromo-2'-deoxyuridine assays with SNK-6 and YT cells, we found that the 5'-bromo-2'-deoxyuridine index was significantly reduced in these cells transduced with miR-150 without additive effects (data not shown).
miR-150, thus, appears to function as a tumor suppressor by increasing cell susceptibility to apoptosis and decreasing cell cycle progression, although the effect does not induce a marked reduction in % GFP.
miR-150 induces senescence in NK/T-cell lymphoma lines
We speculated that the reduction in %GFP among miR-150 transductants during culture might reflect cellular senescence. To test this idea, we transduced miR-150 into cells from the YT, MOTN-1, SNK-6 and HANK-1 lines, which had previously showed reductions in %GFP during culture (Figure 3) . The miR-150 transduction efficiency was about 5-10%, which was Figure 6a ). In addition, these cells stained positively for Ki-67 and senescenceassociated beta-gal on day 21 after GFP selection and miR-150 transductants had a 'fried egg'-like appearance, which is caused by senescence and is not seen in normal NK/T-cell lymphoma cells (data of HANK-1 are shown in Figure 6b ). We also used telomeric repeat amplification protocol assays to assess telomerase activity in MOTN-1, SNK-6 and HANK-1 cells, with and without miR-150 transduction, and in normal NK cells. We found that resting and activated NK cells showed no telomerase activity (Figure 6c ), whereas NK/T-cell lymphoma cell lines did so, indicating a reverse correlation between expression of miR-150 and telomerase activity ( Figure 6c ). As shown in Figure 6d , telomerase activity in miR-150 transductants (on day 21 after GFP selection) was markedly lower than in cells transduced with empty vector. Because it is known that lymphocytes without telomerase activity show telomeric DNA shortening during cell culture, 22 we used Southern blot analysis to assess the telomere length in HANK-1, MOTN-1 and SNK-6 cells. Genomic DNA was digested by HinfI, which does not cleave within the repeating (TTAGGG)n sequence that constitutes the telemetric DNA. 
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A Watanabe et al restriction fragments were then determined by gel electrophoresis followed by Southern analysis using a probe that recognizes this sequence. As shown in Figure 6e , we observed a shortening of telomeric DNA in the cells expressing miR-150 during continuous culture. Indeed, the telemetric restriction fragments of miR-150 transductants grew shorter with every successive passage (Figure 6f ). Thus, miR-150 appears to control aging and senescence in mature lymphocytes.
Identification of direct targets of miR-150 and the downstream targets in NK/T-cell lymphoma
We used Target Scan (http://www.targetscan.org) and Pigtar (http://pictar.mdc-berlin.de) to predict miR-150 targets. 23, 24 We then used western analysis to assess expression in various candidate targets, including c-Myb, We also analyzed expression of the telomerase-related proteins Dyskerin (gene name dyskeratosis congenita 1, DKC1), SirT1, PAI-1, Mre1 and ERCC1, which also possess seed sequences (but not conserved) of miR-150. Of these, loss of Dyskerin function is known to induce senescence. 27 We found that levels of both AKT2 and Dyskerin were reduced in all miR-150 transductants (Figure 7a ), whereas BCAP expression was slightly reduced in SNK-6 and HANK-1 cells (data not shown). To determine whether these proteins are direct targets of miR-150, we carried out luciferase reporter assays in Rat-1 fibroblasts stably expressing miR-150. Upon insertion of the wild-type 3 0 -UTR of DKC1, PIK3AP1, AKT3 or AKT2 into the reporter, we observed significant reductions in luciferase activity with DKC1, PIK3AP1 and AKT2, but not in AKT3 (data not shown), as compared with cells transduced with empty vector (control vector), suggesting that DKC1, PIK3AP1 (data not shown) and AKT2 have potential to function as direct targets of miR-150 (Figure 7b) .
Overexpression of AKT2 with upregulation of pAKT ser474 , which enhances telomerase activity through phosphorylation of human telomerase reverse transcript (hTERT), has been observed in various cancers. 28, 29 We therefore carried out a western analysis of pAKT ser473/4 expression and found it to be markedly reduced in the cells tested. We also detected upregulation of (Figure 7c ). Bim is a BH3 proapoptotic protein and its upregulation can lead to apoptosis. 30 Upregulation of these tumor suppressors might be linked to pAKT downregulation, although further study will be needed to determine whether or not these changes in expression are pAKT-dependent.
Discussion
Recent studies have shown deregulations of coding genes in NK/ T-cell lymphoma.
14,31,32 However, there are no reports of miRNA deregulations in these subtypes. In this study, we assessed miR-150 expression in NK cell and CD56 þ T-cell lymphomas, and found it to be significantly reduced. Although aberrantly low expression of miR-150 has been identified in Sezary syndrome, 33 which is classified as a T-cell lymphoma, there have been no reports on its expression and function during NK/T-cell lymphomagenesis. Almost none of the tested cell lines and primary samples of NK/T-cell lymphoma showed expression of miR-150, though mature T and NK cells normally expressed high levels of miR-150, 34 suggesting downregulation miR-150 in lymphomas might be important for lymphomagenesis and contribute to immortalization of the cancer cells. It is also known that normal lymphocytes show senescence with increasing population doublings. 22 Our results suggest that the continuous expression of miR-150 in normal mature lymphocytes may be required to prevent immortalization, which may be a first step toward developing cancer.
Our findings also suggest that downregulation of miR-150 can lead to activation of telomerase via upregulation of AKT2, a prosurvival protein serine/threonine kinase activated via the PI3K pathway, which is a key prosurvival pathway in cancer. 28, 29, [35] [36] [37] [38] [39] Several studies have shown that AKT2 gene is overexpressed in various tumor cell lines and human malignancies, including B-cell lymphoma, liver, ovarian, pancreatic and breast cancers; and that overexpression of AKT2 protein is associated with increased invasion and metastasis. [35] [36] [37] [38] [39] Thus, AKT2 appears to have a crucial role in tumorigenesis.
Activation of the PI3K-AKT pathway through phosphorylation of Serine 474 in AKT2 is strongly associated with tumorigenesis. For example, pAKT ser473/4 can upregulate telomerase via phosphorylation of hTERT, resulting in immortalization of cancer cells. Kang et al 40 reported that the hTERT subunit has two AKT kinase phosphorylation sites (Ser473 and Thr308 in AKT1/AKT3, Ser474 and Thr309 in AKT2) and that pAKT contributes to telomerase activity through phosphorylation of hTERT. Conversely, inhibition of PI3K-AKT signaling reduces telomerase activity. For example, Plunkett et al. 41 reported that, in T cells, the loss of telomerase activity is associated with reduced levels of pAKT ser473/4 . It is also known that inhibition of AKT signaling by p27 induces a senescence-like arrest, independent of p53. 42 Consistent with those reports, our results strongly suggest that activation (phosphorylation) of AKT due to the loss of miR-150 expression may have a key role in enhancing human telomerase activity in the cancer cells.
Interestingly, forced expression of miR-150 can also lead to downregulation of DKC1/Dyekerin in NK/T-cell lymphoma cells, suggesting that loss of miR-150 may activate Dyskerin. It is encoded by DKC1 and is a predominantly nucleolar protein essential for the formation of pseudouridine in RNA and the telomerase RNA subunit hTR. 43, 44 Dyskeratosis congenita patients have a nonsense mutation within DKC1, leading to diminished expression of Dyskerin accompanied by downregulation of telomerase activity. 45 Overexpression of DKC1 has been seen in solid tumors, and the silencing of DKC1 can reduce telomerase activity and rRNA pseudouridylation. 46 ,47 These findings suggest that the level of Dyskerin expression parallels the activation and inactivation of telomerase. Together, activation of hTERT via pAKT and the continuous expression of Dyskerin could contribute to the enhancement of telomerase activity; however, it is still unclear whether the reduced expression of Dyskerin leads directly to inactivation of telomerase or whether telomerase is regulated via miR-150 itself.
In the present study, we do not address the mechanism underlying the loss of miR-150 expression in NK/T-cell Tumor suppressor miR-150 in malignant lymphoma A Watanabe et al lymphomas. We can say, however, that it is likely not the result of genomic alteration and/or an epigenetic mechanism, such as deletion or methylation/deacetylation. Fluorescence in situ hybridization analysis of 19q31.33 in all eleven NK/T-cell lymphoma cell lines revealed no genomic deletion, and 5-Aza-2 0 -deoxycydine (a DNA methyltransferase inhibitor) and/or trichostatin A (a histone deacetylase inhibitor) did not restore miR-150 activity in these lymphoma cells (data not shown). Previously, Chang et al. 48 showed that miR-150 is downregulated by c-Myc and that miR-150 may function as a tumor suppressor, asw injection of mouse lymphoma cell lines into mice expressing miR-150 produced fewer tumor cells in vivo. We used Northern and western blot analyses to examine c-Myc expression in NK (YT, KAI-3, MOTN-1, SNK-6 and HANK-1) and B-cell (Raji and Daudi) lymphoma lines (these cell lines showed no expression of miR-150). Although the B-cell lymphoma lines strongly expressed c-Myc, two (KAI-3, and YT) of the five NK-cell lymphoma lines did not express c-Myc (Supplementary Figure 4) . Given that these two cell lines also did not express miR-150, it is not likely that the downregulation of miR-150 was due to c-Myc, at least not in these cells. This suggests there is another regulator of miR-150.
We previously demonstrated that miR-21 and/or miR-155 are overexpressed in NK-cell lymphomas. 13 These miRNAs, respectively, downregulate the phosphatases PTEN and SHIP1, leading to activation of the PI3K-AKT pathway. In earlier studies 13 and the present one, we found that miR-21 could function as an oncomiR by enhancing anti-apoptotic activity in NK-cell tumors, and that the effect was strengthened when miR-21 functioned cooperatively with miR-150. Our findings also indicate that transduction of miR-155 alone did not increase oncogenic activity, despite a slight upregulation of pAKT. However, our observation that knockdown of miR-155 alone increased the incidence of apoptosis cells when it was expressed with miR-150 suggests that miR-155 may serve as an oncomiR, though its activity is weaker than that of miR-21 or miR-150. This suggests miR-155 may function as an enhancer of oncomiRs in NK cell tumors. Our earlier findings showed that expression of miR-21 and miR-155 is mutually exclusive in both NK cell lines and primary tumors from patients. 13 In the present study, we found that miR-150 is downregulated in both NK cell lines and primary tumors. These oncomiRs may function cooperatively to enable the continuous activation of PI3K-AKT signaling, ultimately leading to enhancing anti-apoptotic activity, cell cycle progression, cell proliferation and immortalization via targeting of downstream mediators such as hTERT, p53 and Bim.
In summary, we have shown that miR-150 functions as a tumor suppressor in NK/T-cell lymphomas. Our results also suggest that miR-150 likely serves as an upstream regulator of the PI3K-AKT pathway. These findings could provide a basis for new therapies targeting AKT in the treatment of NK/T-cell lymphoma.
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